Statins ||| S:0 E:7 ||| NNP
,  ||| S:7 E:9 ||| ,
fracture  ||| S:9 E:18 ||| JJ
risk ||| S:18 E:22 ||| NN
,  ||| S:22 E:24 ||| ,
and  ||| S:24 E:28 ||| CC
bone  ||| S:28 E:33 ||| NN
remodeling  ||| S:33 E:44 ||| NN
Statins  ||| S:44 E:52 ||| NNS
inhibit  ||| S:52 E:60 ||| VBP
HMG-CoA  ||| S:60 E:68 ||| JJ
reductase  ||| S:68 E:78 ||| NN
and  ||| S:78 E:82 ||| CC
reduce  ||| S:82 E:89 ||| VB
the  ||| S:89 E:93 ||| DT
intracellular  ||| S:93 E:107 ||| JJ
formation  ||| S:107 E:117 ||| NN
of  ||| S:117 E:120 ||| IN
mevalonate ||| S:120 E:130 ||| NN
.  ||| S:130 E:132 ||| .
They  ||| S:132 E:137 ||| PRP
are  ||| S:137 E:141 ||| VBP
chemical  ||| S:141 E:150 ||| JJ
compounds  ||| S:150 E:160 ||| JJ
able  ||| S:160 E:165 ||| JJ
to  ||| S:165 E:168 ||| TO
reduce  ||| S:168 E:175 ||| VB
total  ||| S:175 E:181 ||| JJ
cholesterol  ||| S:181 E:193 ||| NN
by  ||| S:193 E:196 ||| IN
15-40 ||| S:196 E:201 ||| CD
%  ||| S:201 E:203 ||| NN
and  ||| S:203 E:207 ||| CC
LDL  ||| S:207 E:211 ||| NNP
cholesterol  ||| S:211 E:223 ||| NN
by  ||| S:223 E:226 ||| IN
20-60 ||| S:226 E:231 ||| CD
% ||| S:231 E:232 ||| NN
,  ||| S:232 E:234 ||| ,
and  ||| S:234 E:238 ||| CC
to  ||| S:238 E:241 ||| TO
increase  ||| S:241 E:250 ||| VB
HDL  ||| S:250 E:254 ||| JJ
cholesterol  ||| S:254 E:266 ||| NN
by  ||| S:266 E:269 ||| IN
5-15 ||| S:269 E:273 ||| CD
% ||| S:273 E:274 ||| NN
.  ||| S:274 E:276 ||| .
They  ||| S:276 E:281 ||| PRP
also  ||| S:281 E:286 ||| RB
reduce  ||| S:286 E:293 ||| VB
triglycerides  ||| S:293 E:307 ||| VBN
by  ||| S:307 E:310 ||| IN
10-  ||| S:310 E:314 ||| CD
30 ||| S:314 E:316 ||| CD
% ||| S:316 E:317 ||| NN
.  ||| S:317 E:319 ||| .
Statins ||| S:319 E:326 ||| NNP
,  ||| S:326 E:328 ||| ,
blocking  ||| S:328 E:337 ||| VBG
the  ||| S:337 E:341 ||| DT
mevalonate  ||| S:341 E:352 ||| JJ
pathway ||| S:352 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
inhibit  ||| S:361 E:369 ||| VBP
the  ||| S:369 E:373 ||| DT
prenylation  ||| S:373 E:385 ||| NN
of  ||| S:385 E:388 ||| IN
proteins ||| S:388 E:396 ||| NNS
,  ||| S:396 E:398 ||| ,
which  ||| S:398 E:404 ||| WDT
is  ||| S:404 E:407 ||| VBZ
essential  ||| S:407 E:417 ||| JJ
to  ||| S:417 E:420 ||| TO
perform  ||| S:420 E:428 ||| VB
their  ||| S:428 E:434 ||| PRP$
biological  ||| S:434 E:445 ||| JJ
function ||| S:445 E:453 ||| NN
.  ||| S:453 E:455 ||| .
A  ||| S:455 E:457 ||| DT
great  ||| S:457 E:463 ||| JJ
deal  ||| S:463 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
research  ||| S:471 E:480 ||| NN
has  ||| S:480 E:484 ||| VBZ
documented  ||| S:484 E:495 ||| VBN
the  ||| S:495 E:499 ||| DT
positive  ||| S:499 E:508 ||| JJ
effect  ||| S:508 E:515 ||| NN
of  ||| S:515 E:518 ||| IN
statins  ||| S:518 E:526 ||| NN
on  ||| S:526 E:529 ||| IN
bone  ||| S:529 E:534 ||| NN
formation  ||| S:534 E:544 ||| NN
and  ||| S:544 E:548 ||| CC
the  ||| S:548 E:552 ||| DT
importance  ||| S:552 E:563 ||| NN
of  ||| S:563 E:566 ||| IN
bone  ||| S:566 E:571 ||| FW
morphogenetic  ||| S:571 E:585 ||| FW
protein-2  ||| S:585 E:595 ||| FW
( ||| S:595 E:596 ||| -LRB-
BMP-2 ||| S:596 E:601 ||| NNP
)  ||| S:601 E:603 ||| -RRB-
in  ||| S:603 E:606 ||| IN
mediating  ||| S:606 E:616 ||| VBG
this  ||| S:616 E:621 ||| DT
effect ||| S:621 E:627 ||| NN
.  ||| S:627 E:629 ||| .
Statins  ||| S:629 E:637 ||| NNS
are  ||| S:637 E:641 ||| VBP
also  ||| S:641 E:646 ||| RB
able  ||| S:646 E:651 ||| JJ
to  ||| S:651 E:654 ||| TO
decrease  ||| S:654 E:663 ||| VB
osteoblast  ||| S:663 E:674 ||| JJ
apoptosis ||| S:674 E:683 ||| NN
.  ||| S:683 E:685 ||| .
The  ||| S:685 E:689 ||| DT
positive  ||| S:689 E:698 ||| JJ
effect  ||| S:698 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
statins  ||| S:708 E:716 ||| NN
on  ||| S:716 E:719 ||| IN
bone  ||| S:719 E:724 ||| NN
formation  ||| S:724 E:734 ||| NN
is  ||| S:734 E:737 ||| VBZ
accompanied  ||| S:737 E:749 ||| VBN
by  ||| S:749 E:752 ||| IN
an  ||| S:752 E:755 ||| DT
inhibition  ||| S:755 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
osteoclast  ||| S:769 E:780 ||| JJ
activity ||| S:780 E:788 ||| NN
,  ||| S:788 E:790 ||| ,
which  ||| S:790 E:796 ||| WDT
gives  ||| S:796 E:802 ||| VBZ
statins  ||| S:802 E:810 ||| VBG
the  ||| S:810 E:814 ||| DT
ability  ||| S:814 E:822 ||| NN
to  ||| S:822 E:825 ||| TO
uncouple  ||| S:825 E:834 ||| VB
the  ||| S:834 E:838 ||| DT
bone  ||| S:838 E:843 ||| NN
remodeling  ||| S:843 E:854 ||| NN
processes ||| S:854 E:863 ||| NNS
.  ||| S:863 E:865 ||| .
Patients  ||| S:865 E:874 ||| NNS
taking  ||| S:874 E:881 ||| VBG
statins  ||| S:881 E:889 ||| NNS
have  ||| S:889 E:894 ||| VBP
a  ||| S:894 E:896 ||| DT
higher  ||| S:896 E:903 ||| JJR
femoral  ||| S:903 E:911 ||| JJ
bone  ||| S:911 E:916 ||| NN
density  ||| S:916 E:924 ||| NN
than  ||| S:924 E:929 ||| IN
those  ||| S:929 E:935 ||| DT
who  ||| S:935 E:939 ||| WP
do  ||| S:939 E:942 ||| VBP
not ||| S:942 E:945 ||| RB
.  ||| S:945 E:947 ||| .
The  ||| S:947 E:951 ||| DT
lipophilic  ||| S:951 E:962 ||| JJ
statins  ||| S:962 E:970 ||| NNS
seem  ||| S:970 E:975 ||| VBP
to  ||| S:975 E:978 ||| TO
be  ||| S:978 E:981 ||| VB
more  ||| S:981 E:986 ||| RBR
effective  ||| S:986 E:996 ||| JJ
than  ||| S:996 E:1001 ||| IN
the  ||| S:1001 E:1005 ||| DT
hydrophilic  ||| S:1005 E:1017 ||| JJ
statins  ||| S:1017 E:1025 ||| NN
in  ||| S:1025 E:1028 ||| IN
protecting  ||| S:1028 E:1039 ||| VBG
bone ||| S:1039 E:1043 ||| NN
.  ||| S:1043 E:1045 ||| .
In  ||| S:1045 E:1048 ||| IN
several  ||| S:1048 E:1056 ||| JJ
clinical  ||| S:1056 E:1065 ||| JJ
trials ||| S:1065 E:1071 ||| NNS
,  ||| S:1071 E:1073 ||| ,
but  ||| S:1073 E:1077 ||| CC
not  ||| S:1077 E:1081 ||| RB
in  ||| S:1081 E:1084 ||| IN
all ||| S:1084 E:1087 ||| DT
,  ||| S:1087 E:1089 ||| ,
the  ||| S:1089 E:1093 ||| DT
use  ||| S:1093 E:1097 ||| NN
of  ||| S:1097 E:1100 ||| IN
statins  ||| S:1100 E:1108 ||| NN
had  ||| S:1108 E:1112 ||| VBD
been  ||| S:1112 E:1117 ||| VBN
associated  ||| S:1117 E:1128 ||| VBN
with  ||| S:1128 E:1133 ||| IN
a  ||| S:1133 E:1135 ||| DT
reduction  ||| S:1135 E:1145 ||| NN
in  ||| S:1145 E:1148 ||| IN
the  ||| S:1148 E:1152 ||| DT
fracture  ||| S:1152 E:1161 ||| JJ
risk ||| S:1161 E:1165 ||| NN
.  ||| S:1165 E:1167 ||| .
In  ||| S:1167 E:1170 ||| IN
conclusion ||| S:1170 E:1180 ||| NN
,  ||| S:1180 E:1182 ||| ,
statins  ||| S:1182 E:1190 ||| NNS
have  ||| S:1190 E:1195 ||| VBP
a  ||| S:1195 E:1197 ||| DT
positive  ||| S:1197 E:1206 ||| JJ
effect  ||| S:1206 E:1213 ||| NN
on  ||| S:1213 E:1216 ||| IN
bone  ||| S:1216 E:1221 ||| NN
in  ||| S:1221 E:1224 ||| IN
vitro ||| S:1224 E:1229 ||| NN
,  ||| S:1229 E:1231 ||| ,
but  ||| S:1231 E:1235 ||| CC
such  ||| S:1235 E:1240 ||| PDT
an  ||| S:1240 E:1243 ||| DT
efficacy  ||| S:1243 E:1252 ||| NN
in  ||| S:1252 E:1255 ||| IN
humans  ||| S:1255 E:1262 ||| NNS
has  ||| S:1262 E:1266 ||| VBZ
yet  ||| S:1266 E:1270 ||| RB
to  ||| S:1270 E:1273 ||| TO
be  ||| S:1273 E:1276 ||| VB
clearly  ||| S:1276 E:1284 ||| RB
demonstrated ||| S:1284 E:1296 ||| VBN
.  ||| S:1296 E:1298 ||| .
Randomized ||| S:1298 E:1308 ||| NNP
,  ||| S:1308 E:1310 ||| ,
controlled  ||| S:1310 E:1321 ||| VBN
trials  ||| S:1321 E:1328 ||| NNS
are  ||| S:1328 E:1332 ||| VBP
needed  ||| S:1332 E:1339 ||| VBN
to  ||| S:1339 E:1342 ||| TO
provide  ||| S:1342 E:1350 ||| VB
a  ||| S:1350 E:1352 ||| DT
satisfactory  ||| S:1352 E:1365 ||| JJ
answer  ||| S:1365 E:1372 ||| NN
on  ||| S:1372 E:1375 ||| IN
this  ||| S:1375 E:1380 ||| DT
issue ||| S:1380 E:1385 ||| NN
.  ||| S:1385 E:1387 ||| .
